Announce interim data from the ARV-110 ARDENT Phase 2 expansion at 420 mg

Deadline passed; outcome being checked

Announced: 1 Mar 2021
Due: 31 Dec 2021
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“Announcement of interim data from the ARDENT Phase 2 dose expansion at 420 mg (2H21)”

SourceArvinas, Inc. Form 8-K press release, 2021-03-01
FilingSEC filing index
Deadline as stated2H21
Deadline used31 Dec 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-ARVN-024846
Cite as https://keptindex.org/c/KI-C-2021-ARVN-024846/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Announce
Deliverable: ARV-110 ARDENT Phase 2 interim data announcement
Target: 420 mg
In the company’s control: Medium
Specificity: High

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Arvinas, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-ARVN-024846 · Corrections policy